drugset / Trial / NCT02393547

Lorcaserin for Preventing Weight Gain Among Smokers

NCT02393547

Phase 1/2 Completed 20 enrolled Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

This will be an open label clinical trial with all subjects receiving both lorcaserin and varenicline with a primary aim of reducing post cessation weight gain.

Timeline

Start
2013-09
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lorcaserin Small molecule 10 mg
Subject Varenicline Small molecule 1 mg

Indications